GLP-1 Weight Loss Medication Cost in India 2026

Ozempic (Novo Nordisk) starts at ₹1,415 per weekly injection, which works out to ₹5,660 per month for the 0.25 mg starter pen. That is the price after Novo Nordisk's April 2026 cut of roughly 23.8 percent across doses, triggered by the generic semaglutide launch on 20 March 2026. The 0.5 mg pen is around ₹7,760 per month and the 1 mg maintenance pen is around ₹8,500 per month. Every figure is the official India MRP, not an imported quote.

Yes, generic semaglutide is roughly four times cheaper than Ozempic. Natco's Semanat vial starts at ₹325 per weekly dose (about ₹1,300 per month), Glenmark's GLIPIQ vial is also ₹325 per week, and Alkem's Semasize pen sits at ₹450 per week. Ozempic (Novo Nordisk) starts at ₹1,415 per week. Bloomberg reported the patent expiry on 20 March 2026 has brought weekly costs as low as $14. The molecule is identical; the price gap reflects branding, pen vs vial format, and Novo Nordisk's premium positioning.

The cheapest GLP-1 in India is generic semaglutide in vial format. Natco's Semanat and Glenmark's GLIPIQ both retail at ₹325 per weekly dose, or roughly ₹1,300 per month. Pen-format generics like Alkem's Semasize cost ₹450 per week. These are CDSCO-approved Subsequent New Drugs released after the 20 March 2026 patent expiry. The trade-off: vial format requires a separate syringe and slightly more dosing care than a pre-filled pen, so first-time patients usually start on a pen even at the higher price.

Mounjaro (Eli Lilly) starts at ₹3,281 per weekly injection, which is ₹13,125 per month for the 2.5 mg starter dose. The 5 mg dose costs ₹16,406 per month, 7.5 mg and 10 mg both sit at ₹20,625 per month, and the highest doses of 12.5 mg and 15 mg cost ₹25,781 per month. Eli Lilly launched the KwikPen in India in August 2025. As of October 2025 Mounjaro became the top-selling drug in Indian pharma at ₹100 crore monthly sales, which is why no price cut has been announced.

Yes, Wegovy (Novo Nordisk) has been available in India since June 2025 and is the only obesity-indication semaglutide approved by CDSCO. After Novo's April 2026 cut of up to 48 percent, the 0.25 mg starter pen is ₹5,660 per month. The 0.5 mg dose runs ₹7,200 to ₹8,800 monthly, 1.0 mg is ₹8,800 to ₹10,800, and the 1.7 mg maintenance dose is ₹12,000 to ₹14,400 per month. Most patients titrate up over 16 weeks, so the realistic month-one cost is the starter price, not the maintenance price.

No. As of May 2026, no IRDAI-regulated health insurance policy in India covers GLP-1 medication for obesity. Indian policies are hospitalisation-first products. Outpatient injectables fall outside standard cover, and weight-loss drugs are treated as non-medical expenses by Star Health, ICICI Lombard, HDFC ERGO and Niva Bupa. The narrow exception is OPD-rider plans like Star Health Diabetes Safe that may reimburse semaglutide when prescribed by an endocrinologist for confirmed Type 2 diabetes, but each claim is adjudicated against policy wording, and obesity-only prescriptions are uniformly excluded.

The starting cost is roughly ₹6,500 to ₹8,500 for the first month, broken down as follows. A telemedicine consultation with a DermaVue physician is ₹1,499. Baseline labs run ₹1,500 to ₹2,500 depending on the panel and city (Thyrocare Aarogyam B at ₹1,449, Redcliffe metabolic combo at ₹999 to ₹1,499). Generic semaglutide for the first month is ₹1,300 to ₹1,800. If you choose Ozempic instead of generic, the medication line item rises to ₹5,660. Cold-chain delivery is included by most pharmacies above ₹1,000 order value.

The honest answer is yes, but they are predictable, not hidden. Plan for these four line items beyond the medication itself. First, baseline labs at ₹1,500 to ₹2,500 (CBC, HbA1c, lipid panel, TSH, creatinine, lipase). Second, follow-up labs at month 3 and month 6 of similar cost. Third, dose escalation every 4 to 8 weeks may move you to a more expensive pen or vial strength. Fourth, anti-emetics like ondansetron 4 mg cost ₹40 to ₹100 per strip and are often needed in weeks 1 through 6. None of these are surprises if your prescribing physician maps them out at consultation.